Recurrent Non-small Cell Lung Cancer Completed Phase 2 Trials for Dasatinib (DB01254)

Also known as: Non-Small Cell Lung Cancer Recurrent / Lung cancer non-small cell recurrent

IndicationStatusPhase
DBCOND0028805 (Recurrent Non-small Cell Lung Cancer)Completed2
clinicaltrials.gov IdentifierTitlePurposeDrugs
NCT00459342Dasatinib in Treating Patients With Stage IIIB, Stage IV, or Recurrent Non-Small Cell Lung CancerTreatment